Retatrutide, by Soma Pharmaceuticals , represents a exciting development in weight control . This dual-action drug combines GLP-1 receptor agonist function with GIP receptor agonist activation , indicating remarkable results in patient findings for metabolic improvement. Researchers believe Retatrutide is expected to represent a alternative option